Pinteon Therapeutics is advancing clinical studies of a novel antibody that aims to interrupt the spread of toxic tau and protect and preserve brain function in patients with neurodegenerative disease. Pinteon’s lead asset, PNT001, is the only antibody in development that targets cis-pT231 tau, a neurotoxic epitope which has been identified in multiple preclinical studies as a potent driver of neurodegenerative disease. Pinteon is led by an experienced management team with strong track records in CNS drug discovery and development and is funded by Morningside Ventures. For more information, visit pinteon.com.
Company Details
- Employees
- 3
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Keywords
- Kinnear Pharmaceuticals.
Pinteon Therapeutics Questions
Pinteon Therapeutics's LinkedIn profile is https://www.linkedin.com/company/pinteon-therapeutics
Pinteon Therapeutics has
3 employees.
View email and phone details for 3
employees at Pinteon Therapeutics.
Pinteon Therapeutics's industry is
Biotechnology Research
Pinteon Therapeutics's top competitors are
Osmol Therapeutics,
Thetis Pharmaceuticals,
Pinotbio, Inc.,
Zurex Pharma,
Simcha Therapeutics,
Kinnear Pharmaceuticals,
Axiom Biopharma,
Capio Biosciences,
Embera Neurotherapeutics,
Hughes Biopharma Advisers Llc Clinical Operations Consulting.
Pinteon Therapeutics's categories are Biotechnology Research
